Publications

Skip to content

Real-world evidence

New and Noteworthy

Powering a new era of treatment with real-world insights on >26K people with ovarian cancer

ovarian 1 -100

Genitourinary cancer research is incredibly promising, and real-world evidence is a key part of it
With real-world evidence, the whole is greater than the sum of its parts
From entry to insights: How AI is transforming the clinical data journey

All the latest

Topics

Data management

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Post marketing requirements

Prospective study

Regulatory

Treatment patterns

Trial design

Unmet need

Content type

Article

Case study

Event recap

Podcast

Publications

Video

Webinar

Showing 9 of 0 results

Flatiron Health announces research to be presented at ASCO 2025
Genitourinary cancer research is incredibly promising, and real-world evidence is a key part of it
Powering a new era of treatment with real-world insights on >26K people with ovarian cancer
The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Cancer
Flatiron Health announces research to be presented at ISPOR 2025
With real-world evidence, the whole is greater than the sum of its parts
- Real-world evidence
- Case study
From data to decisions: the role of real-world evidence in recent multiple myeloma drug approvals in the US and EU
ISPOR
Leveraging machine learning to assess the association of rash and survival in patients with advanced NSCLC
ISPOR
Performance assessment and validation of real-world response data generated using a deep learning-based natural language processing model across multiple solid tumors
ISPOR

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Clinical Research
Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Data Confidentiality Commitments
Cookie Settings
© FLATIRON HEALTH® 2025